Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
A

Ratings ESG MSCI

Ratings Novo Nordisk A/S: Strengths and Weaknesses

  • According to MSCI, the company's ESG score for its industry is good.
Highlights: Novo Nordisk A/S
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Novo Nordisk A/S
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Novo Nordisk A/S SectorDenmark
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Novo Nordisk A/S SectorDenmark
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Novo Nordisk A/S SectorDenmark
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Novo Nordisk A/S SectorDenmark
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Novo Nordisk A/S SectorDenmark
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
21TCr
A
89TCr
A
49TCr
BBB
39TCr
AA
34TCr
AA
28TCr
A
25TCr
AAA
25TCr
A
17TCr
A
15TCr
AAA
Average 34.19TCr
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Ratings Novo Nordisk A/S